Exome Asset Management LLC Makes New $1.03 Million Investment in Trevi Therapeutics, Inc. $TRVI

Key Points

• Exome Asset Management LLC has acquired a new stake in Trevi Therapeutics, purchasing 163,738 shares valued at approximately $1.03 million, representing about 0.16% ownership in the company.
• Shares of Trevi Therapeutics have seen an increase of 8.4%, with current trading around $7.60 and a market cap of approximately $925.53 million.
• Analysts have issued mixed ratings on Trevi Therapeutics, with the average target price set at $21.75, reflecting a consensus recommendation of "Buy" from multiple research firms.

Exome Asset Management LLC acquired a new position in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 163,738 shares of the company's stock, valued at approximately $1,030,000. Exome Asset Management LLC owned approximately 0.16% of Trevi Therapeutics at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of the stock. Raymond James Financial Inc. acquired a new stake in shares of Trevi Therapeutics in the fourth quarter valued at about $49,000. Dimensional Fund Advisors LP boosted its holdings in Trevi Therapeutics by 86.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 134,353 shares of the company's stock worth $553,000 after acquiring an additional 62,143 shares during the period. Price T Rowe Associates Inc. MD grew its position in Trevi Therapeutics by 32.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 25,166 shares of the company's stock valued at $104,000 after acquiring an additional 6,119 shares in the last quarter. Northern Trust Corp raised its stake in shares of Trevi Therapeutics by 11.3% during the fourth quarter. Northern Trust Corp now owns 482,815 shares of the company's stock valued at $1,989,000 after purchasing an additional 49,173 shares during the period. Finally, Ameriprise Financial Inc. lifted its position in shares of Trevi Therapeutics by 187.0% during the fourth quarter. Ameriprise Financial Inc. now owns 96,784 shares of the company's stock worth $399,000 after purchasing an additional 63,067 shares in the last quarter. Hedge funds and other institutional investors own 95.76% of the company's stock.

Trevi Therapeutics Stock Performance

Shares of Trevi Therapeutics stock traded down $1.50 during trading on Friday, reaching $8.25. The company had a trading volume of 3,619,982 shares, compared to its average volume of 2,751,478. Trevi Therapeutics, Inc. has a fifty-two week low of $2.36 and a fifty-two week high of $9.92. The firm's fifty day moving average is $7.36 and its 200-day moving average is $6.52. The company has a market cap of $1.00 billion, a price-to-earnings ratio of -19.64 and a beta of 0.71.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.01. On average, research analysts anticipate that Trevi Therapeutics, Inc. will post -0.49 EPS for the current fiscal year.

Analysts Set New Price Targets

TRVI has been the subject of a number of recent analyst reports. Wall Street Zen lowered shares of Trevi Therapeutics from a "hold" rating to a "sell" rating in a report on Friday, June 6th. Morgan Stanley started coverage on Trevi Therapeutics in a research note on Thursday, August 21st. They set an "overweight" rating and a $18.00 target price for the company. Cantor Fitzgerald began coverage on Trevi Therapeutics in a research note on Tuesday, July 1st. They issued an "overweight" rating and a $25.00 price target on the stock. D. Boral Capital reissued a "buy" rating and issued a $21.00 price target on shares of Trevi Therapeutics in a report on Monday, June 2nd. Finally, Oppenheimer restated an "outperform" rating on shares of Trevi Therapeutics in a report on Monday, June 2nd. One analyst has rated the stock with a Strong Buy rating and seven have assigned a Buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $21.75.

Trevi Therapeutics Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.